Pieter Cullis, PhD

Chairman & Scientific Advisor  

Dr. Pieter Cullis, co-founder of Integrated Nanotherapeutics and Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia, has been responsible for fundamental advances in the generation, loading and targeting of lipid nanoparticle (LNP) systems for intravenous delivery of small molecule drugs and genetic drugs. These efforts have led to three drugs (Abelcet, Myocet and Marqibo) that have been approved by regulatory agencies in the U.S. and Europe for the treatment of cancer and its complications and seven more (Alocrest, Brakiva, LNP-Ciprofloxacin, MNK-010, ALN-VSP, ALN-PCS, ALN-TTR) that are in clinical trials. Dr. Cullis has also been extensively involved in founding companies to commercialize technologies. He co-founded and served on the board of the Canadian Liposome Company, Inex Pharmaceuticals (now Tekmira Pharmaceuticals), Northern Lipids Inc., Lipex Biomembranes Inc., and, most recently, Acuitas Pharmaceuticals and Precision NanoSystems. In addition, he co-founded and was Scientific Director of the Centre for Drug Research and Development (CDRD). Dr. Cullis is also the co-founder of the BC Personalized Medicine Initiative (PMI). He has published over 300 papers and holds over 45 separate patents.